top of page
Helping patients understand KRAS cancer research.
KRAS Cancer News & Updates
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Terri Conneran KRAS Kickers
Sep 28
What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri
Terri Conneran KRAS Kickers
Jun 10, 2025
Rare Pancreas cancer FGFR + KRAS trial - comes to you
Rare Pancreatic cancer trial comes to you! FGFR + KRAS
Terri Conneran KRAS Kickers
May 19, 2025
Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Where can patients find the NCCN guidelines used to guide cancer treatment?
NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.
bottom of page